際際滷

際際滷Share a Scribd company logo
RATIONAL OPTIMISM
IN
RESEARCH & DEVELOPMENT
Dennis Lendrem
RATIONAL OPTIMISM
IN
RESEARCH & DEVELOPMENT
Dennis Lendrem
Lendrem D.W., Senn S.J., Lendrem B.C., Isaacs J.D. (2015),
R&D productivity rides again?, Pharmaceut. Statist., 14, 13, doi: 10.1002/pst.1653
Lendrem D., Senn S.J., Lendrem B.C., and Isaacs J.D. (2015), R&D productivity rides
again?, Pharmaceut. Statist., 14, 13, doi: 10.1002/pst.1653
Years
Cycle Time
= 4 yrs
1
2
3
4
5
6
Cycle Time
= 6 yrs
1
2
3
4
5
6
Before After
Years
Cycle Time
= 4 yrs
1
2
3
4
5
6
Cycle Time
= 6 yrs
1
2
3
4
5
6
Before After
Rational Optimism
 By placing tasks in parallel to reduce cycle time we
inadvertently:
 Increased R&D costs
 Increased late-stage attrition rates
 Increased expected time to market
Rational Optimism
 By placing tasks in parallel to reduce cycle time we
inadvertently:
 Increased R&D costs
 Increased late-stage attrition rates
 Increased expected time to market
Lendrem DW, Lendrem BC Torching the Haystack: Modelling fast-fail strategies in drug
development. Drug Discov Today. 2013 Apr;18(7-8):331-6.
http://dx.doi.org/10.1016/j.drudis.2012.11.011
Lendrem DW, Lendrem BC The Development Speed Paradox: Can increasing development
speed reduce R&D productivity? Drug Discov Today. 2014 Mar;9(3):209-214
http://dx.doi.org/10.1016/j.drudis.2013.09.002
Rational Optimism
Looking for a needle in a haystack?
Torch the haystack.
Rational Optimism
 It is more important to do the right science than to do
the wrong science quickly.
 Build opportunities to kill projects earlier in the
development cycle.
 Focus on tests that prevent projects from entering the
development process.
 Focus on tests that allow elimination of projects early
in the development process.
Rational Optimism
Rational Optimism
 Progression Bias
 terminations are viewed as losses and project teams are loss-
averse
 sunk-costs fallacy  terminating a project risks losing investment
that has already been lost
 marginal cost associated with a decision to continue development
may seem trivial compared to the losses associated with
terminating a potential NTD
 organizational and market incentives to load the pipeline with
promising candidates
 Progression bias leads to continued development even in
the light of strong evidence supporting termination.
Rational Optimism
 Rational Optimism
 Continued pursuit of a line of research in the knowledge that it is
likely to be successful.
Rational Optimism
 Rational Optimism
 Continued pursuit of a line of research in the knowledge that it is
likely to be successful.
 Mindless Optimism
 Continued pursuit of a line of research in the hope that it will be
successful.
R&D Progression Bias and Rational Optimism
Rational Optimism
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Rational Optimism
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Rational Optimism
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Rational Optimism
 Opportunity Costs:
Loss due to false negatives = B
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Rational Optimism
 Opportunity Costs:
Loss due to false negatives = B
Loss due to false positives = C
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Rational Optimism
 Opportunity Costs:
Loss due to false negatives = B
Loss due to false positives = CxA
NTD
p
1-硫 A
硫 B
1-p
留 C
1-留 D
Success
Miss
False
Discovery
Success
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Positives
when 留 = 67%
硫 =10%
mindless
optimism
rational
optimismvs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
硫 =15%Cost of False Positives
when 留 = 67%
mindless
optimism
rational
optimismvs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
mindless
optimism
rational
optimism 硫 =20%
Cost of False Positives
when 留 = 67%
vs
Rational Optimism
 So?
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Positives
when 留 = 67%
Cost of False Negatives
when 硫 =10%
mindless
optimism
rational
optimism
vs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
mindless
optimism
rational
optimism Cost of False Negatives
when 硫 =20%
Cost of False Positives
when 留 = 67%
vs
The false negative rate has to be rather high before it outweighs
the cost of false positives!
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
硫 =20%
Cost of False Positives
when 留 = 67%
mindless
optimism
rational
optimismvs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
硫 =20%
mindless
optimism
rational
optimismvs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
硫 =20%
mindless
optimism
rational
optimismvs
Rational Optimism
 So?
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Negatives
when 硫 =20%
Cost of False Positives
when 留 = 67%
mindless
optimism
rational
optimism
vs
Opportunity
Costs
(%)
Probability (%)
20
15
10
5
0
25 -
-
-
-
-
-
0 20 40 60 80 100
I I I I I I
Cost of False Negatives
when 硫 =20%
mindless
optimism
rational
optimism
vs
Early Development Late Development
Rational Optimism
 So?
 We fear false negatives, but the opportunity costs of false positives
are huge.
 Terminating projects frees up R&D resources to pursue other
prospects.
 Thinking about opportunity costs allows project teams to reframe
termination decisions as prospective future gains.
Rational Optimism
Lendrem D.W., Lendrem B.C., Peck R.W., Senn S.J., Day, S., Isaacs J.D. (2015),
Progression Bias and Rational Optimism in Research & Development,
Nat. Rev. Drug Discov., In press
NTD
p
1-硫1
1-硫2
1-硫3
1-硫4
1-硫5
1-硫6
1-硫7
1-硫8
硫8
硫7
硫6
硫5
硫4
硫3
硫2
硫1
1-p
留1
留2
留3
留4
留5
留6
留7
留8
1-留8
1-留7
1-留6
1-留5
1-留4
1-留3
1-留2
1-留1
Rational Optimism
 Richard Peck (Roche)
 Stephen Senn (CRP Sant辿)
 Simon Day (MHRA)
 John Isaacs (MRG)
 John Loughlin (MRG)
NIHR Newcastle BRC
Rational Optimism
 Richard Peck (Roche)
 Stephen Senn (CRP Sant辿)
 Simon Day (MHRA)
 John Isaacs (MRG)
 John Loughlin (MRG)
 Clare Lendrem (AHG)
NIHR Newcastle BRC
fin

More Related Content

Similar to R&D Progression Bias and Rational Optimism (20)

The Art of Estimating - Andy Nolan
The Art of Estimating - Andy NolanThe Art of Estimating - Andy Nolan
The Art of Estimating - Andy Nolan
Association for Project Management
Risk And Relevance 20080414ppt
Risk And Relevance 20080414pptRisk And Relevance 20080414ppt
Risk And Relevance 20080414ppt
gregoryg
Risk And Relevance 20080414ppt
Risk And Relevance 20080414pptRisk And Relevance 20080414ppt
Risk And Relevance 20080414ppt
gregoryg
What are the odds of making that number risk analysis with crystal ball - O...
What are the odds of making that number   risk analysis with crystal ball - O...What are the odds of making that number   risk analysis with crystal ball - O...
What are the odds of making that number risk analysis with crystal ball - O...
p6academy
Startup finance: valuation of tech companies
Startup finance: valuation of tech companiesStartup finance: valuation of tech companies
Startup finance: valuation of tech companies
Rianne Vogels
Company Valuation and Metrics top down or bottom up?
Company Valuation and Metrics  top down or bottom up?Company Valuation and Metrics  top down or bottom up?
Company Valuation and Metrics top down or bottom up?
The Capital Network
Risk analysis Chapter
Risk analysis ChapterRisk analysis Chapter
Risk analysis Chapter
SINGHZEE
Yetizen presentation on LTV
Yetizen presentation on LTVYetizen presentation on LTV
Yetizen presentation on LTV
Lloyd Melnick
Fixing inequalities fast with recruitment tech
Fixing inequalities fast with recruitment techFixing inequalities fast with recruitment tech
Fixing inequalities fast with recruitment tech
Renu Gundala
LinkedIn for Business Development SourceIn London, James Osborne
LinkedIn for Business Development SourceIn London, James OsborneLinkedIn for Business Development SourceIn London, James Osborne
LinkedIn for Business Development SourceIn London, James Osborne
LinkedIn For Search and Recruitment Firms
Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech "Statistical Literacy for Deep Tech"Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech
Writing the Killer Business Case for Database and Analytics Investment
 Writing the Killer Business Case for Database and Analytics Investment Writing the Killer Business Case for Database and Analytics Investment
Writing the Killer Business Case for Database and Analytics Investment
89Degrees
Using Analytics To Make Smart HR Decisions
Using Analytics To Make Smart HR DecisionsUsing Analytics To Make Smart HR Decisions
Using Analytics To Make Smart HR Decisions
BambooHR
DocTrain West - Business of Experience
DocTrain West - Business of ExperienceDocTrain West - Business of Experience
DocTrain West - Business of Experience
Jess McMullin
Portfolio growth gap assessment
Portfolio growth gap assessmentPortfolio growth gap assessment
Portfolio growth gap assessment
The Inovo Group
Lesson 4 pp4.ppt
Lesson 4 pp4.pptLesson 4 pp4.ppt
Lesson 4 pp4.ppt
podge82
1530 track1 rosenbaum
1530 track1 rosenbaum1530 track1 rosenbaum
1530 track1 rosenbaum
Rising Media, Inc.
Winning in the SaaS Economy
Winning in the SaaS EconomyWinning in the SaaS Economy
Winning in the SaaS Economy
SaaStock
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
LinkedIn Talent Solutions
Bias and overconfidence in oil and gas exploration
Bias and overconfidence in oil and gas explorationBias and overconfidence in oil and gas exploration
Bias and overconfidence in oil and gas exploration
Graeme Keith
Risk And Relevance 20080414ppt
Risk And Relevance 20080414pptRisk And Relevance 20080414ppt
Risk And Relevance 20080414ppt
gregoryg
Risk And Relevance 20080414ppt
Risk And Relevance 20080414pptRisk And Relevance 20080414ppt
Risk And Relevance 20080414ppt
gregoryg
What are the odds of making that number risk analysis with crystal ball - O...
What are the odds of making that number   risk analysis with crystal ball - O...What are the odds of making that number   risk analysis with crystal ball - O...
What are the odds of making that number risk analysis with crystal ball - O...
p6academy
Startup finance: valuation of tech companies
Startup finance: valuation of tech companiesStartup finance: valuation of tech companies
Startup finance: valuation of tech companies
Rianne Vogels
Company Valuation and Metrics top down or bottom up?
Company Valuation and Metrics  top down or bottom up?Company Valuation and Metrics  top down or bottom up?
Company Valuation and Metrics top down or bottom up?
The Capital Network
Risk analysis Chapter
Risk analysis ChapterRisk analysis Chapter
Risk analysis Chapter
SINGHZEE
Yetizen presentation on LTV
Yetizen presentation on LTVYetizen presentation on LTV
Yetizen presentation on LTV
Lloyd Melnick
Fixing inequalities fast with recruitment tech
Fixing inequalities fast with recruitment techFixing inequalities fast with recruitment tech
Fixing inequalities fast with recruitment tech
Renu Gundala
Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech "Statistical Literacy for Deep Tech"Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech "Statistical Literacy for Deep Tech"
Impact.Tech
Writing the Killer Business Case for Database and Analytics Investment
 Writing the Killer Business Case for Database and Analytics Investment Writing the Killer Business Case for Database and Analytics Investment
Writing the Killer Business Case for Database and Analytics Investment
89Degrees
Using Analytics To Make Smart HR Decisions
Using Analytics To Make Smart HR DecisionsUsing Analytics To Make Smart HR Decisions
Using Analytics To Make Smart HR Decisions
BambooHR
DocTrain West - Business of Experience
DocTrain West - Business of ExperienceDocTrain West - Business of Experience
DocTrain West - Business of Experience
Jess McMullin
Portfolio growth gap assessment
Portfolio growth gap assessmentPortfolio growth gap assessment
Portfolio growth gap assessment
The Inovo Group
Lesson 4 pp4.ppt
Lesson 4 pp4.pptLesson 4 pp4.ppt
Lesson 4 pp4.ppt
podge82
Winning in the SaaS Economy
Winning in the SaaS EconomyWinning in the SaaS Economy
Winning in the SaaS Economy
SaaStock
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
One Team: LinkedIn Talent Leadership Keynote | Pat Wadors & Brendan Browne Ta...
LinkedIn Talent Solutions
Bias and overconfidence in oil and gas exploration
Bias and overconfidence in oil and gas explorationBias and overconfidence in oil and gas exploration
Bias and overconfidence in oil and gas exploration
Graeme Keith

Recently uploaded (20)

Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic As...
Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic As...Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic As...
Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic As...
PVI, PeerView Institute for Medical Education
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptxIntroduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
hepopolomolok2023
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical SignificanceEnzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
SumeetSharma591398
Understanding Trauma: Causes, Effects, and Healing Strategies
Understanding Trauma: Causes, Effects, and Healing StrategiesUnderstanding Trauma: Causes, Effects, and Healing Strategies
Understanding Trauma: Causes, Effects, and Healing Strategies
Becoming Institute
Macafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Reviews 2024 - Macafem for Menopause SymptomsMacafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Supplement
psychosomaticdisorder and it's physiotherapy management
psychosomaticdisorder and it's physiotherapy managementpsychosomaticdisorder and it's physiotherapy management
psychosomaticdisorder and it's physiotherapy management
Dr Shiksha Verma (PT)
An overview of Acute Myeloid Leukemia in Lesotho Preliminary National Tum...
An overview  of  Acute Myeloid Leukemiain Lesotho Preliminary National Tum...An overview  of  Acute Myeloid Leukemiain Lesotho Preliminary National Tum...
An overview of Acute Myeloid Leukemia in Lesotho Preliminary National Tum...
SEJOJO PHAAROE
The influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcomeThe influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcome
lksharma10797
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptxRabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Wahid Husein
Syncope in dentistry.pptx
Syncope in dentistry.pptxSyncope in dentistry.pptx
Syncope in dentistry.pptx
Dr Kingshika Joylin
Mastering Mobility- Joints of Lower Limb -Dr. Ahmed Elzainy.pdf
Mastering Mobility- Joints of Lower Limb -Dr. Ahmed Elzainy.pdfMastering Mobility- Joints of Lower Limb -Dr. Ahmed Elzainy.pdf
Mastering Mobility- Joints of Lower Limb -Dr. Ahmed Elzainy.pdf
Internal medicine department, faculty of Medicine Beni-Suef University Egypt
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
ABHAY INSTITUTION
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLuminaIncreased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Ulana Rey PharmD
Role of Artificial Intelligence in Clinical Microbiology.pptx
Role of Artificial Intelligence in Clinical Microbiology.pptxRole of Artificial Intelligence in Clinical Microbiology.pptx
Role of Artificial Intelligence in Clinical Microbiology.pptx
Dr Punith Kumar
Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy W...
Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy W...Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy W...
Restoring Remission in RRMM: Present and Future of Sequential Immunotherapy W...
PVI, PeerView Institute for Medical Education
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical SignificanceEnzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
SumeetSharma591398
E Book Daniya Sanal.pdf#healthy books.com
E Book Daniya Sanal.pdf#healthy books.comE Book Daniya Sanal.pdf#healthy books.com
E Book Daniya Sanal.pdf#healthy books.com
DaniyaSanal
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
PeerVoice
Tongue carcinoma presentation ENT
Tongue    carcinoma   presentation   ENTTongue    carcinoma   presentation   ENT
Tongue carcinoma presentation ENT
ENTHTJS
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdfUnion Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
AditiAlishetty
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptxIntroduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
Introduction-to-the-PuroKalusugan-InitiativeCHD12.pptx
hepopolomolok2023
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical SignificanceEnzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples, and Clinical Significance
SumeetSharma591398
Understanding Trauma: Causes, Effects, and Healing Strategies
Understanding Trauma: Causes, Effects, and Healing StrategiesUnderstanding Trauma: Causes, Effects, and Healing Strategies
Understanding Trauma: Causes, Effects, and Healing Strategies
Becoming Institute
Macafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Reviews 2024 - Macafem for Menopause SymptomsMacafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Reviews 2024 - Macafem for Menopause Symptoms
Macafem Supplement
psychosomaticdisorder and it's physiotherapy management
psychosomaticdisorder and it's physiotherapy managementpsychosomaticdisorder and it's physiotherapy management
psychosomaticdisorder and it's physiotherapy management
Dr Shiksha Verma (PT)
An overview of Acute Myeloid Leukemia in Lesotho Preliminary National Tum...
An overview  of  Acute Myeloid Leukemiain Lesotho Preliminary National Tum...An overview  of  Acute Myeloid Leukemiain Lesotho Preliminary National Tum...
An overview of Acute Myeloid Leukemia in Lesotho Preliminary National Tum...
SEJOJO PHAAROE
The influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcomeThe influence of birth companion in mother care and neonatal outcome
The influence of birth companion in mother care and neonatal outcome
lksharma10797
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptxRabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Rabies Bali 2008-2020_WRD Webinar_WSAVA 2020_Final.pptx
Wahid Husein
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
PERSONALITY DEVELOPMENT & DEFENSE MECHANISMS.pptxPersonality and environment:...
ABHAY INSTITUTION
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLuminaIncreased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Increased Clinical Trial Complexity | Dr. Ulana Rey | MindLumina
Ulana Rey PharmD
Role of Artificial Intelligence in Clinical Microbiology.pptx
Role of Artificial Intelligence in Clinical Microbiology.pptxRole of Artificial Intelligence in Clinical Microbiology.pptx
Role of Artificial Intelligence in Clinical Microbiology.pptx
Dr Punith Kumar
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical SignificanceEnzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
Enzyme Induction and Inhibition: Mechanisms, Examples & Clinical Significance
SumeetSharma591398
E Book Daniya Sanal.pdf#healthy books.com
E Book Daniya Sanal.pdf#healthy books.comE Book Daniya Sanal.pdf#healthy books.com
E Book Daniya Sanal.pdf#healthy books.com
DaniyaSanal
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations ...
PeerVoice
Tongue carcinoma presentation ENT
Tongue    carcinoma   presentation   ENTTongue    carcinoma   presentation   ENT
Tongue carcinoma presentation ENT
ENTHTJS
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdfUnion Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
Union Budget 2025 Healthcare Sector Analysis & Impact (PPT).pdf
AditiAlishetty

R&D Progression Bias and Rational Optimism

  • 1. RATIONAL OPTIMISM IN RESEARCH & DEVELOPMENT Dennis Lendrem
  • 2. RATIONAL OPTIMISM IN RESEARCH & DEVELOPMENT Dennis Lendrem
  • 3. Lendrem D.W., Senn S.J., Lendrem B.C., Isaacs J.D. (2015), R&D productivity rides again?, Pharmaceut. Statist., 14, 13, doi: 10.1002/pst.1653
  • 4. Lendrem D., Senn S.J., Lendrem B.C., and Isaacs J.D. (2015), R&D productivity rides again?, Pharmaceut. Statist., 14, 13, doi: 10.1002/pst.1653
  • 5. Years Cycle Time = 4 yrs 1 2 3 4 5 6 Cycle Time = 6 yrs 1 2 3 4 5 6 Before After
  • 6. Years Cycle Time = 4 yrs 1 2 3 4 5 6 Cycle Time = 6 yrs 1 2 3 4 5 6 Before After
  • 7. Rational Optimism By placing tasks in parallel to reduce cycle time we inadvertently: Increased R&D costs Increased late-stage attrition rates Increased expected time to market
  • 8. Rational Optimism By placing tasks in parallel to reduce cycle time we inadvertently: Increased R&D costs Increased late-stage attrition rates Increased expected time to market Lendrem DW, Lendrem BC Torching the Haystack: Modelling fast-fail strategies in drug development. Drug Discov Today. 2013 Apr;18(7-8):331-6. http://dx.doi.org/10.1016/j.drudis.2012.11.011 Lendrem DW, Lendrem BC The Development Speed Paradox: Can increasing development speed reduce R&D productivity? Drug Discov Today. 2014 Mar;9(3):209-214 http://dx.doi.org/10.1016/j.drudis.2013.09.002
  • 9. Rational Optimism Looking for a needle in a haystack? Torch the haystack.
  • 10. Rational Optimism It is more important to do the right science than to do the wrong science quickly. Build opportunities to kill projects earlier in the development cycle. Focus on tests that prevent projects from entering the development process. Focus on tests that allow elimination of projects early in the development process.
  • 12. Rational Optimism Progression Bias terminations are viewed as losses and project teams are loss- averse sunk-costs fallacy terminating a project risks losing investment that has already been lost marginal cost associated with a decision to continue development may seem trivial compared to the losses associated with terminating a potential NTD organizational and market incentives to load the pipeline with promising candidates Progression bias leads to continued development even in the light of strong evidence supporting termination.
  • 13. Rational Optimism Rational Optimism Continued pursuit of a line of research in the knowledge that it is likely to be successful.
  • 14. Rational Optimism Rational Optimism Continued pursuit of a line of research in the knowledge that it is likely to be successful. Mindless Optimism Continued pursuit of a line of research in the hope that it will be successful.
  • 16. Rational Optimism NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 17. Rational Optimism NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 18. Rational Optimism NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 19. Rational Optimism Opportunity Costs: Loss due to false negatives = B NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 20. Rational Optimism Opportunity Costs: Loss due to false negatives = B Loss due to false positives = C NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 21. Rational Optimism Opportunity Costs: Loss due to false negatives = B Loss due to false positives = CxA NTD p 1-硫 A 硫 B 1-p 留 C 1-留 D Success Miss False Discovery Success
  • 22. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I Cost of False Positives when 留 = 67% 硫 =10% mindless optimism rational optimismvs
  • 23. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I 硫 =15%Cost of False Positives when 留 = 67% mindless optimism rational optimismvs
  • 24. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I mindless optimism rational optimism 硫 =20% Cost of False Positives when 留 = 67% vs
  • 25. Rational Optimism So? Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I Cost of False Positives when 留 = 67% Cost of False Negatives when 硫 =10% mindless optimism rational optimism vs Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I mindless optimism rational optimism Cost of False Negatives when 硫 =20% Cost of False Positives when 留 = 67% vs The false negative rate has to be rather high before it outweighs the cost of false positives!
  • 26. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I 硫 =20% Cost of False Positives when 留 = 67% mindless optimism rational optimismvs
  • 27. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I 硫 =20% mindless optimism rational optimismvs
  • 28. Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I 硫 =20% mindless optimism rational optimismvs
  • 29. Rational Optimism So? Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I Cost of False Negatives when 硫 =20% Cost of False Positives when 留 = 67% mindless optimism rational optimism vs Opportunity Costs (%) Probability (%) 20 15 10 5 0 25 - - - - - - 0 20 40 60 80 100 I I I I I I Cost of False Negatives when 硫 =20% mindless optimism rational optimism vs Early Development Late Development
  • 30. Rational Optimism So? We fear false negatives, but the opportunity costs of false positives are huge. Terminating projects frees up R&D resources to pursue other prospects. Thinking about opportunity costs allows project teams to reframe termination decisions as prospective future gains.
  • 31. Rational Optimism Lendrem D.W., Lendrem B.C., Peck R.W., Senn S.J., Day, S., Isaacs J.D. (2015), Progression Bias and Rational Optimism in Research & Development, Nat. Rev. Drug Discov., In press NTD p 1-硫1 1-硫2 1-硫3 1-硫4 1-硫5 1-硫6 1-硫7 1-硫8 硫8 硫7 硫6 硫5 硫4 硫3 硫2 硫1 1-p 留1 留2 留3 留4 留5 留6 留7 留8 1-留8 1-留7 1-留6 1-留5 1-留4 1-留3 1-留2 1-留1
  • 32. Rational Optimism Richard Peck (Roche) Stephen Senn (CRP Sant辿) Simon Day (MHRA) John Isaacs (MRG) John Loughlin (MRG) NIHR Newcastle BRC
  • 33. Rational Optimism Richard Peck (Roche) Stephen Senn (CRP Sant辿) Simon Day (MHRA) John Isaacs (MRG) John Loughlin (MRG) Clare Lendrem (AHG) NIHR Newcastle BRC
  • 34. fin

Editor's Notes

  • #8: As a result, the industry became really slick at delivering late-stage failures to the market place, precipitating the current R&D productivity crisis.
  • #9: As a result, the industry became really slick at delivering late-stage failures to the market place, precipitating the current R&D productivity crisis.
  • #11: 10